Having trouble accessing articles? Reset your cache.

Epizyme looks to sarcoma for first approval

More than a decade after it was founded and after nearly $1 billion raised, Epizyme has submitted its first NDA to FDA for a small molecule inhibitor of an epigenetic cancer target. The company is seeking accelerated approval of EZH2

Read the full 409 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers